Cyclin D1 expression in ductal carcinoma of the breast and its correlation with other prognostic parameters

Journal of Cancer Research and Therapeutics

Volumn 10, Issue 3, 2014, Pages 671-675

  Ravikumar, Gayatri ^a   Ananthamurthy, Anuradha ^a  

^a ST JOHN'S NATIONAL ACADEMY OF HEALTH SCIENCES   (India)

Author keywords

Breast; cyclin D1; ductal carcinoma; immunohistochemistry; prognostic factors

Indexed keywords

CYCLIN D1; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; HORMONE RECEPTOR; PROGESTERONE RECEPTOR; TUMOR MARKER;

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; AXILLARY LYMPH NODE METASTASIS; BREAST CARCINOMA; CANCER PATIENT; CANCER PROGNOSIS; CHEMICAL PARAMETERS; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE SEVERITY; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; LYMPH NODE METASTASIS; MIDDLE AGED; PREDICTIVE VALUE; PROTEIN EXPRESSION; STAINING; TRIPLE NEGATIVE BREAST CANCER; TUMOR CELL; TUMOR VOLUME; BREAST TUMOR; CANCER GRADING; CANCER STAGING; GENE EXPRESSION; GENETICS; METABOLISM; METASTASIS; PAGET NIPPLE DISEASE; PATHOLOGY; PROGNOSIS; RISK FACTOR;

ADULT; AGED; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CYCLIN D1; FEMALE; GENE EXPRESSION; HUMANS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RISK FACTORS; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL;

EID: 84920167890     PISSN: 09731482     EISSN: 19984138     Source Type: Journal    
DOI: 10.4103/0973-1482.138135     Document Type: Article

References (20)

1. Lee A, Park WC, Yim HW, Lee MA, Park G, Lee KY. Expression of c-erbB2, cyclin D1 and estrogen receptor and their clinical implications in the invasive ductal carcinoma of the breast. Jpn J Clin Oncol 2007;37:708-14.
2. Hicks DG, Dawson A, Mattingly S, Crowe JP. The unmet clinical need for new molecular genetic markers in the prognosis and therapeutic management of breast cancer. Arch Pathol Lab Med 2005;129:1372-4.
3. Ellis IO, Schnitt SJ, Sastre-Garau X, Bussolati G, Tavassoli FA, Eusebi V, et al. Invasive breast carcinoma. In: Tavassoli FA, Devilee P, editors. World Health Organization Classification of Tumours Pathology and Genetics of Tumours of the Breast and Female Genital Organs. Lyon: IARC Press; 2003. p. 20.
4. Arnold A, Papanikolaou A. Cyclin D1 in breast cancer pathogenesis. J Clin Oncol 2005;23:4215-24.
5. Kenny FS, Hui R, Musgrove EA, Gee JM, Blamey RW, Nicholson RI, et al. Overexpression of cyclin D1 messenger RNA predicts for poor prognosis in estrogen receptor-positive breast cancer. Clin Cancer Res 1999;5:2069-76.
6. Joe AK, Memeo L, Mckoy J, Mansukhani M, Liu H, Avila-Bront A, et al. Cyclin D1 overexpression is associated with estrogen receptor expression in Caucasian but not African-American breast cancer. Anticancer Res 2005;25:273-81.
7. Yu Q, Geng Y, Sicinski P. Specific protection against breast cancers by cyclin D1 ablation. Nature 2001;411:1017-21.
8. Sutherland RL, Musgrove EA. Cyclin D1 and mammary carcinoma: New insights from transgenic mouse models. Breast Cancer Res 2002;4:14-7.
9. Joe AK, Arber N, Zhang Y, Heitjan T, Han E, Sgambato A, et al. Over expression of Cyclin D1 in breast cancer, clinical and pathologic correlations. ASCO Annual Meeting. 1998.
10. Hwang TS, Han HS, Hong YC, Lee HJ, Paik NS. Prognostic value of combined analysis of cyclin D1 and estrogen receptor status in breast cancer patients. Pathol Int 2003;53:74-80.
11. Zukerberg LR, Yang WI, Gadd M, Thor AD, Koerner FC, Schmidt EV, et al. Cyclin D1 (PRAD1) protein expression in breast cancer: Approximately one-Third of infiltrating mammary carcinomas show overexpression of the cyclin D1 oncogene. Mod Pathol 1995;8:560-7.
12. Zhang SY, Caamano J, Cooper F, Guo X, Klein-Szanto AJ. Immunohistochemistry of cyclin D1 in human breast cancer. Am J Clin Pathol 1994;102:695-8.
13. Alle KM, Henshall SM, Field AS, Sutherland RL. Cyclin D1 protein is overexpressed in hyperplasia and intraductal carcinoma of the breast. Clin Cancer Res 1998;4:847-54.
14. Reis-Filho JS, Savage K, Lambros MB, James M, Steele D, Jones RL, et al. Cyclin D1 protein overexpression and CCND1 amplification in breast carcinomas: An immunohistochemical and chromogenic in situ hybridisation analysis. Mod Pathol 2006;19:999-1009.
15. McGuire WL. Breast cancer prognostic factors: Evaluation guidelines. J Natl Cancer Inst 1991;83:154-5.
16. Clark GM. Prognostic and predictive factors. In: Harris JR, Lippman ME, Morrow M, OsborneCK.(eds):Diseases of the Breast. Philadelphia, PA: Lippincott-Raven; 1996. p. 461-85.
17. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. Adopted on May 17, 1996 by the American Society of Clinical Oncology. J Clin Oncol 1996;14:2843-77.
18. Bardou VJ, Arpino G, Elledge RM, Osborne CK, Clark GM. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol 2003;21:1973-9.
19. Patil VW, Singhai R, Patil AV, Gurav PD. Triple-negative (ER, PgR, HER-2/neu) breast cancer in Indian women. Breast Cancer: Targets and Therapy 2011;3:9-19.
20. Kim MJ, Ro JY, Ahn SH, Kim HH, Kim SB, Gong G. Clinicopathologic significance of the basal-like subtype of breast cancer: A comparison with hormone receptor and Her2/neu-overexpressing phenotypes. Hum Pathol 2006;37:1217-26.